WillisH.NavarroMD(He/Him)
Hematology • Tucson, AZHematologic Oncology
VP, Head of Clinical Development and Pharmacovigilance Aadi Bioscience, Inc.
Dr. Navarro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3838 N Campbell Ave
Bldg 1
Tucson, AZ 85719Phone+1 520-694-2873
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1995 - 1998
Yale-New Haven Medical CenterResidency, Internal Medicine, 1990 - 1993- University of California San Francisco School of MedicineClass of 1990
Certifications & Licensure
AZ State Medical License 2023 - 2027
CA State Medical License 1995 - 2026
MN State Medical License 2019 - 2025- American Board of Internal Medicine Hematology
Clinical Trials
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer Start of enrollment: 1999 Jan 01
- Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab Start of enrollment: 2017 Dec 29
- Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy Start of enrollment: 2017 Dec 29
Publications & Presentations
PubMed
- 2 citationsImmune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 TrialPolina Shindiapina, Maciej Pietrzak, Michal Seweryn, Eric McLaughlin, Xiaoli Zhang
Frontiers in Immunology. 2021-09-03 - 23 citationsAllogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.Richard F. Ambinder, Juan Wu, Brent R. Logan, Christine M. Durand, Ryan K. Shields
Biology of Blood and Marrow Transplantation. 2019-11-01 - 40 citationsFirst-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.Jessica J. Tao, Nicholas A. Cangemi, Vicky Makker, Karen Cadoo, Joyce F. Liu
Clinical Cancer Research. 2019-09-15
Abstracts/Posters
- Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematop...Willis Navarro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803...Willis H. Navarro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
